Recent news items are general market and macroeconomic updates without direct reference to Beacon Topco or its planned business combination.

• Dollar fell and gold rallied as US CPI trailed estimates, reflecting macroeconomic conditions [N1].
• Oil prices climbed to a one-month high amid U.S. and Iran trade attacks in the Strait of Hormuz, impacting energy markets [N2].
• Stocks were supported as bond yields slid on a weak CPI report, indicating market reactions to inflation data [N3].
• Google expanded Gemini in Chrome in the UK, reflecting technology sector developments [N4].
• Elon Musk's Tesla posted its best quarter in two years, highlighting notable corporate performance [N5].
• Stocks rallied on a Fed-friendly CPI report, showing market sensitivity to central bank signals [N6].
• Broadcom shares fell as strong AI results failed to lift guidance, indicating sector-specific challenges [N7].
• Wheat prices faced losses at midday, reflecting commodity market fluctuations [N8].

The company is positioned to complete a strategic business combination that consolidates Barinthus Biotherapeutics plc and Clywedog Therapeutics, potentially creating a stronger entity with combined resources and capabilities. The listing on Nasdaq under the ticker 'CLYD' may provide access to public capital markets and increased visibility.

The company has not commenced operations and carries no assets or revenues, making it dependent on the successful completion of the planned transactions. Delays or failure in consummating the business combination could impede progress and value creation. As a shell entity, it currently lacks operational history or financial performance.

As a newly formed entity with no operations or assets, Beacon Topco currently has no established competitive advantages or economic moat. Its value proposition is tied to the successful completion of the planned business combination and the prospects of the combined entity thereafter.

• Transaction Completion Risk: The company's future depends on successfully completing the planned business combination with Barinthus Bio and Clywedog Therapeutics. Failure or delays could adversely affect the company.
• Operational Inactivity: Beacon Topco has not commenced operations and has no assets or liabilities, which means it currently lacks operational history and revenue generation.
• Market Listing and Regulatory Risks: The company plans to list on Nasdaq post-transaction, which involves regulatory compliance and market risks that could impact its public status and investor perception.

• Beacon Topco, Inc. is a Delaware corporation formed on September 24, 2025, as a wholly-owned direct subsidiary of Barinthus Biotherapeutics plc.
• The company has one wholly-owned direct subsidiary, Cdog Merger Sub, Inc., a Delaware corporation.
• Beacon Topco, Inc. has not commenced operations and has no assets or liabilities as of June 30, 2026.
• The company was formed for the purpose of consummating a business combination (the Transactions) with Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc., a Delaware corporation.
• On September 29, 2025, Beacon Topco entered into an Agreement and Plan of Merger with Barinthus Bio, Merger Sub, and Clywedog, amended on February 22, 2026.
• The Transactions involve Beacon Topco acquiring all outstanding share capital of Barinthus Bio via a scheme of arrangement under UK law, and Merger Sub merging with and into Clywedog, with Clywedog surviving as a wholly-owned subsidiary of Beacon Topco.
• Upon closing, Barinthus Bio shareholders are expected to own approximately 34% and Clywedog stockholders approximately 66% of Beacon Topco on a fully diluted basis, based on capitalizations at the date of the Merger Agreement.
• The Transactions have been unanimously approved by the boards of directors of Barinthus Bio and Clywedog.
• Beacon Topco plans to change its name to Clywedog Therapeutics Holdings, Inc. following completion of the Transactions.
• At closing, Beacon Topco's common stock will be listed on the Nasdaq Stock Market under the ticker symbol 'CLYD'.
• As of June 30, 2026, Beacon Topco was authorized to issue 100 shares of common stock, all of which were issued and outstanding and held by Barinthus Bio.
• The company has filed a Registration Statement on Form S-4 with the SEC, declared effective on April 22, 2026, to register shares to be issued in connection with the Transactions.
• Beacon Topco is a non-accelerated filer, a smaller reporting company, and an emerging growth company as of the latest filing.
• The company has no reported revenues, operating expenses, net income, or cash and cash equivalents as of June 30, 2026.
• The company has no current assets, liabilities, or other financial activity as it has not commenced operations.
• The company's disclosure controls and procedures were concluded effective as of the end of the period covered by the latest report.
• No changes in internal control over financial reporting materially affecting effectiveness were reported during the current fiscal quarter.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.